The chair of Harvard Medical School’s bioinformatics department, Isaac Kohane, M.D., Ph.D., highlighted that artificial intelligence (AI) is poised to make its most significant initial impact in the healthcare sector through billing and reimbursement. Here are the main points: AI in Healthcare: Contrary to popular belief that AI would first revolutionize diagnosis or data analysis, Kohane believes its primary influence will be in the financial aspects of healthcare, specifically billing and reimbursement. Billing and Reimbursement: AI’s deterministic and discrete data capabilities make it well-suited for managing these areas. Kohane predicts that many healthcare professionals currently working for insurance companies to…
Author: Abhay Panchal
NEW YORK – Laboratory services provider Stone Diagnostics will offer Fibronostics’ artificial intelligence-based liver disease test to physicians in the US, the companies announced on Tuesday. The Liverfast test uses artificial intelligence and 10 blood-based biomarkers to provide information about the degree of fibrosis, steatosis, and activity of a patient’s liver, the companies said in a statement. The strategic partnership “gives us the comprehensive, efficient, reproducible, and scalable laboratory operations platform required to meet increasing Liverfast demand and allows us to focus on the most important needs of our prescribers and their patients,” Brock Smith, Fibronostics general manager for the…
A new DNA test system, the Common Hereditary Cancers Panel by Invitae Corp., has been granted marketing authorization by the US Food and Drug Administration (FDA). This system evaluates an individual’s genetic predisposition for certain cancers and is the first of its kind to receive such authorization. Here are the main points: Test Overview: The test uses next-generation sequencing to assess germline human genomic DNA extracted from a single blood sample. The system detects substitutions, small insertion and deletion alterations, and copy number variants in a panel of 47 targeted genes. Validation: The test’s approval followed the FDA’s review of…
Researchers have found that high levels of serum anti-tissue transglutaminase IgA (tTG-IgA) can predict duodenal villous atrophy, potentially serving as a reliable measure to bypass biopsy in diagnosing adult patients with suspected celiac disease. Here are the main points: Background: The prevalence and incidence of celiac disease (CeD) are on the rise globally. Traditional diagnosis involves specific serology and an intestinal biopsy. However, the accuracy of gluten-specific serology is high, while histology, which requires upper endoscopy, remains operator-dependent. Study Details: In a multicenter prospective study involving 436 adults suspected of having celiac disease, the accuracy of serum tTG-IgA as a…
Although the use of robotic-assisted cholecystectomy increased 37-fold from 2010 to 2019, the procedure was associated with significantly higher rates of bile duct injury compared with laparoscopic cholecystectomy, according to research.
Seven people have been diagnosed with colorectal cancer after health authorities conducted nearly 1,100 repeat colonoscopies for patients who received defective treatment across four years.
The U.S. Food and Drug Administration (FDA) has announced the establishment of a new Digital Health Advisory Committee. This committee aims to provide insights and expertise on the rapidly evolving digital health landscape, including areas like artificial intelligence, machine learning, augmented and virtual reality, digital therapeutics, wearables, and remote patient monitoring. Key Highlights:
Researchers at the Mayo Clinic, led by Panagiotis Korfiatis, PhD, have developed an artificial intelligence (AI) model that shows promise in detecting early-stage, “hidden” pancreatic cancer in asymptomatic individuals. This could pave the way for timely surgical interventions and potential cures. Here are the main findings: In essence, the AI model developed by Mayo Clinic researchers offers a promising tool for early detection of pancreatic cancer, potentially leading to timely interventions and improved patient outcomes.
The article discusses the potential and challenges of new anti-obesity medications, particularly semaglutide and tirzepatide. Here are the main points: Emergence of New Medications: Highly effective anti-obesity medications like semaglutide and tirzepatide have changed the landscape of obesity treatment, offering hope to those struggling with weight issues. Responsibility in Prescribing: While these medications show promise, prescribing them requires careful consideration. Obesity is a complex disease, and its treatment involves more than just medication. Recommendations for Healthcare Providers: The Power of New Medications: The effectiveness of these new anti-obesity drugs is undeniable. However, as the saying goes, “with great power comes…
Researchers at Penn, including Samiran Mukherjee, chief fellow in gastroenterology at the Perelman School of Medicine, are exploring the potential of the artificial intelligence text generator, ChatGPT, in the medical field. Here are the main takeaways: In essence, while ChatGPT and similar AI tools have shown promise in health care, there’s a need for continuous research and collaboration between medical professionals and software developers to harness their full potential.